Key Inclusion Requirements

1. Male or female ≥ 18 years of age.
2. Patients with r/r TCL per WHO 2022 criteria.
3. Has available tumor tissue or willing to undergo biopsy procedure.
4. CD5 positivity confirmed by local laboratory using an approved diagnostic test or LDT.

Key Exclusion Requirements

1. Sezary syndrome. For other tumor types, if there is a suspicion of significant circulating disease at time of leukapheresis, discuss eligibility with medical monitor prior to proceeding.
2. Contraindication to leukapheresis.
3. Prior treatment with any CD5-targeted therapy.
4. Any evidence of the following active viral infections:
   1. HIV infection.
   2. Chronic hepatitis B virus (cHBV) infection with detectable viral load. Patients with cHBV, who are receiving anti-viral prophylaxis, may be enrolled if they are asymptomatic for >5 days prior to signing informed consent (ICF).
   3. Hepatitis C (HCV) infection with detectable viral load. Patients cured of HCV may be enrolled.